Metabolic-Associated Fatty Liver Disease and Diabetes

Metabolic-associated fatty liver disease (MAFLD) is the hepatic manifestation of metabolic syndrome and affects about 55% of people living with diabetes. MAFLD has been shown to be an individual risk factor for cardiovascular disease and its associated mortality. Although common, MAFLD is often underdiagnosed and not given adequate attention during clinical visits. This review highlights the most recent literature available on the evaluation and management of MAFLD in the presence of diabetes. The more recently available antidiabetic agents including glucagon-like peptide-1 analogs and sodium –glucose cotransporter-2 inhibitors have been shown to effectively manage both diabetes and MAFLD.

Source: Endocrinology and Metabolism Clinics of North America - March 22, 2023 Category: Endocrinology Authors: Nitin Kapoor, Sanjay Kalra Source Type: research